secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001193125-24-072871
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics prices $100M equity offering and private placement
--------------------------------------------------------------------

- Underwritten offering of 14,545,454 shares at $5.50/share; net proceeds ~$74.7M.
- Concurrent private placement of pre-funded warrants to Redmile for ~$20M at $5.499/warrant.
- Total gross proceeds ~$100M; expected close March 21, 2024.
- Net proceeds to fund clinical trials, manufacturing, and working capital.
- BofA Securities, Jefferies, Leerink Partners act as joint bookrunners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/0001193125-24-072871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524072871/d799248d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-072871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer